Vera Therapeutics, Inc. (VERA) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy TranscriptSeeking Alpha • 11/07/25
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of MedicineGlobeNewsWire • 11/06/25
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/05/25
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ETGlobeNewsWire • 10/22/25
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025GlobeNewsWire • 10/17/25
Vera Therapeutics, Inc. (VERA) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/05/25
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/05/25
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/10/25
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/25
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term LoansGlobeNewsWire • 06/03/25
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial DataBenzinga • 06/02/25
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA NephropathyGlobeNewsWire • 06/02/25
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsGlobeNewsWire • 05/06/25
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgANGlobeNewsWire • 04/03/25
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/27/25
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/26/25
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/25
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a BetZacks Investment Research • 11/11/24
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two YearsBenzinga • 10/28/24
Vera Therapeutics Eyes Breakout On Promising Results For Kidney DrugInvestors Business Daily • 10/28/24